FOCINVEZ
Dead / Abandoned — Abandoned — failure to respond (as of 05 Dec 2025)
What this means for you
This application is over — abandoned 20 Nov 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97376937
- Mark type
- Stylized text
- Filed
- 22 Apr 2022
- Published for opposition
- 21 Mar 2023
- Abandoned
- 20 Nov 2025
Goods and services
- Class 035 — Advertising and business services: Brand development and evaluation services in the field of pharmaceutical and healthcare industries and medical fields
Owner
- Spes Pharmaceuticals Inc., Plainsboro, NJ, US
- Spes Pharmaceuticals Inc., North Brunswick, NJ, US
Prosecution history
- 05 Dec 2025 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 05 Dec 2025 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 19 Aug 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 19 Aug 2025 — SU - NON-FINAL ACTION - WRITTEN
- 09 Jul 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 01 Apr 2025 — USE AMENDMENT FILED
- 09 Jul 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 01 Apr 2025 — TEAS STATEMENT OF USE RECEIVED
- 07 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Nov 2024 — SOU EXTENSION 3 GRANTED
- 07 Nov 2024 — SOU EXTENSION 3 FILED
- 07 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 30 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Apr 2024 — SOU EXTENSION 2 GRANTED
- 29 Apr 2024 — SOU EXTENSION 2 FILED